These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 33142805)

  • 1. Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
    Veluswamy P; Wacker M; Scherner M; Wippermann J
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD1/PD-L1 Axis in Uro-oncology.
    Junker K; Eckstein M; Fiorentino M; Montironi R
    Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.
    Weyand CM; Berry GJ; Goronzy JJ
    J Leukoc Biol; 2018 Mar; 103(3):565-575. PubMed ID: 28848042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.
    Awadasseid A; Wu Y; Zhang W
    Life Sci; 2021 Oct; 282():119813. PubMed ID: 34256042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
    Ai L; Chen J; Yan H; He Q; Luo P; Xu Z; Yang X
    Drug Des Devel Ther; 2020; 14():3625-3649. PubMed ID: 32982171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.
    Miyabe C; Dong Y; Ikeda T; Takahashi K; Miyabe Y; Kawakami T
    Sci Rep; 2021 Oct; 11(1):20019. PubMed ID: 34625602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
    Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
    Willemsen M; Melief CJM; Bekkenk MW; Luiten RM
    Front Immunol; 2020; 11():579022. PubMed ID: 33240267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.
    Galván Morales MA; Montero-Vargas JM; Vizuet-de-Rueda JC; Teran LM
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.